Dr. Andrea Small-Howard, Chief Scientific Officer of GBS has said “The ability to use specific combinations of cannabinoids and terpenoids to modulate TRP ion channels in sensory neurons could usher in the beginning of a new era of precision medicines derived from the cannabis plant.”
I couldn’t agree more. Precision medicine is key to the plants sustainability generating synergistic opportunities it can exhibit in potential Patient.
Sensory neurons contain multiple members of Transient Receptor Potential (TRP) ion channel family, detecting pain, inflammation, stress, and noxious environmental signals and relay those signals through activism/de-activism of of calcium, sodium, and magnesium ion gradients across cellular membranes. By studying the responses cannabinoids and terpenoids both individually and in combinations at the level of individual receptors.” GBS has unraveled and reverse engineered mechanisms enabling the future of personalized medications.
I have to say there are only a few that have dared to break the barriers with the research and development, and clearly GBS is empowering the medical community enabling awareness to brands that are hyper focused on the quality and standardization necessary to challenge culture delivering quality products to the market.
99